Kyverna Therapeutics Shares Are Trading Higher After the Company Announced KYV-101 Received FDA IND Clearance for the Treatment of Patients With Treatment-refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial
Kyverna Therapeutics股票上漲，因爲該公司宣佈KYV-101已獲得FDA IND明確，用於治療KYSA-8第二階段試驗中治療難度較大的僵人綜合症患者。